TL1A Promotes Lung Tissue Fibrosis and Airway Remodeling

Area of Science:

• Immunology
• Pulmonology
• Cell Biology

Background:

• Lung fibrosis and tissue remodeling are hallmarks of chronic respiratory diseases like asthma, idiopathic pulmonary fibrosis, and systemic sclerosis.
• Current therapies targeting fibrosis remain limited, highlighting an unmet clinical need.

Purpose of the Study:

• To investigate the role of the TNF superfamily cytokine TL1A and its receptor DR3 in lung fibrosis and tissue remodeling.
• To evaluate the therapeutic potential of blocking the TL1A-DR3 interaction in preclinical models.

Main Methods:

• Utilized mouse models of allergen- and bleomycin-induced airway inflammation.
• Employed antibody (Ab) blocking and genetic deletion of the DR3 receptor.
• Assessed peribronchial smooth muscle mass, lung collagen accumulation, and cellular expression patterns.
• Administered recombinant TL1A to naive mouse airways.
• Examined human lung fibroblasts and bronchial epithelial cells in vitro.

Main Results:

• Neutralization of TL1A or deletion of DR3 significantly reduced peribronchial smooth muscle mass and lung collagen deposition in mouse models.
• TL1A was detected in airways and expressed on various immune and structural cells, while DR3 was found on T cells, immune cells, fibroblasts, and epithelial cells.
• Direct administration of TL1A induced lung remodeling in mice, independent of other immune cells.
• Human lung fibroblasts and bronchial epithelial cells expressing DR3 proliferated and produced fibrotic molecules in response to TL1A.

Conclusions:

• The TL1A-DR3 axis plays a critical role in driving lung fibrosis and tissue remodeling.
• Disrupting the TL1A-DR3 interaction presents a promising therapeutic strategy for fibrotic lung diseases.
• Targeting this pathway could prevent deregulated tissue cell activity in chronic lung conditions.